Cladribine
- Generic Name
- Cladribine
- Brand Names
- Litak, Mavenclad
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12ClN5O3
- CAS Number
- 4291-63-8
- Unique Ingredient Identifier
- 47M74X9YT5
- Background
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
- Indication
For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Cutaneous T-Cell Lymphoma (CTCL), Hairy Cell Leukemia (HCL), Non-Hodgkin's Lymphomas, Active confirmed by clinical features, confirmed by imaging features relapsing multiple sclerosis (MS)
Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT03318419
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China
Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid LeukemiaRelapse Leukemia
- Interventions
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 48
- Registration Number
- NCT03181815
- Locations
- 🇨🇳
Liang Wang, Guangzhou, Guangdong, China
Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- Procedure: Autologous hematopoietic stem cell transplantation
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 93
- Registration Number
- NCT03151876
- Locations
- 🇨🇳
Shan Xi Da Yi Hospital, Taiyuan, Shanxi, China
🇨🇳General Hospital of Lanzhou military command, Lanzhou, Gansu, China
🇨🇳Peking university third hospital, Beijing, Beijing, China
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
- Conditions
- Myelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- Drug: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 53
- Registration Number
- NCT03150004
- Locations
- 🇺🇸
Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm
- Conditions
- Acute Leukemia of Ambiguous LineageMyeloid NeoplasmAcute Myeloid Leukemia
- Interventions
- Biological: Granulocyte Colony-Stimulating FactorOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 50
- Registration Number
- NCT03012672
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
- Conditions
- Mixed Phenotype Acute LeukemiaPreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Myeloid LeukemiaRecurrent High Risk Myelodysplastic SyndromeRefractory High Risk Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia
- Interventions
- Biological: FilgrastimOther: Laboratory Biomarker Analysis
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT02921061
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
- Conditions
- High Grade Malignant NeoplasmPreviously Treated Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2Myeloid NeoplasmBlasts 10 Percent or More of Bone Marrow Nucleated CellsChronic Myelomonocytic Leukemia-2Myelodysplastic Syndrome
- Interventions
- Biological: FilgrastimProcedure: Allogeneic Hematopoietic Stem Cell TransplantationOther: Laboratory Biomarker AnalysisOther: Questionnaire AdministrationRadiation: Total-Body Irradiation
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 30
- Registration Number
- NCT02756572
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Conditions
- Myelodysplastic SyndromeMyeloproliferative NeoplasmAcute Myeloid Leukemiade Novo Myelodysplastic SyndromeAcute Biphenotypic Leukemia
- Interventions
- Biological: FilgrastimOther: Laboratory Biomarker AnalysisOther: Quality-of-Life Assessment
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 84
- Registration Number
- NCT02728050
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT02416908
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndrome
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationOther: Laboratory Biomarker AnalysisProcedure: Peripheral Blood Stem Cell TransplantationOther: Pharmacological Study
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT02250937
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.